HRP20192026T1 - Formulacija tableta od neratinib maleata - Google Patents
Formulacija tableta od neratinib maleata Download PDFInfo
- Publication number
- HRP20192026T1 HRP20192026T1 HRP20192026TT HRP20192026T HRP20192026T1 HR P20192026 T1 HRP20192026 T1 HR P20192026T1 HR P20192026T T HRP20192026T T HR P20192026TT HR P20192026 T HRP20192026 T HR P20192026T HR P20192026 T1 HRP20192026 T1 HR P20192026T1
- Authority
- HR
- Croatia
- Prior art keywords
- mass percent
- weight
- components
- intragranular
- crospovidone
- Prior art date
Links
- 229950008835 neratinib Drugs 0.000 title claims 10
- VXZCUHNJXSIJIM-MEBGWEOYSA-N (z)-but-2-enedioic acid;(e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound OC(=O)\C=C/C(O)=O.C=12C=C(NC(=O)\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 VXZCUHNJXSIJIM-MEBGWEOYSA-N 0.000 title claims 9
- 239000007916 tablet composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims 15
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 13
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 7
- 229960000913 crospovidone Drugs 0.000 claims 7
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 7
- 239000008108 microcrystalline cellulose Substances 0.000 claims 7
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 7
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 7
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 6
- 229940069328 povidone Drugs 0.000 claims 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 4
- 229930195725 Mannitol Natural products 0.000 claims 4
- 239000007884 disintegrant Substances 0.000 claims 4
- 239000000945 filler Substances 0.000 claims 4
- 238000005469 granulation Methods 0.000 claims 4
- 230000003179 granulation Effects 0.000 claims 4
- 239000000594 mannitol Substances 0.000 claims 4
- 235000010355 mannitol Nutrition 0.000 claims 4
- 239000007888 film coating Substances 0.000 claims 3
- 238000009501 film coating Methods 0.000 claims 3
- 235000019359 magnesium stearate Nutrition 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 239000008119 colloidal silica Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 239000003607 modifier Substances 0.000 claims 2
- 239000012748 slip agent Substances 0.000 claims 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960001681 croscarmellose sodium Drugs 0.000 claims 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000012458 free base Substances 0.000 claims 1
- 229940057948 magnesium stearate Drugs 0.000 claims 1
- ZNHPZUKZSNBOSQ-BQYQJAHWSA-N neratinib Chemical compound C=12C=C(NC\C=C\CN(C)C)C(OCC)=CC2=NC=C(C#N)C=1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZNHPZUKZSNBOSQ-BQYQJAHWSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000005507 spraying Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (16)
1. Farmaceutski prihvatljiv pripravak koji sadrži:
granulaciju koja sadrži intragranularne komponente:
(a) 10-70 masenih postotaka neratinib maleata;
(b) 15-65 masenih postotaka jednog ili više punila;
(c) 0-8 masenih postotaka jednog ili više sredstava za raspadanje;
(d) 0.2-8 masenih postotaka jednog ili više sredstava za klizanje;
(e) 5-15 masenih postotaka jednog ili više sredstava za modificiranje površine;
pri čemu se granulacija kombinira s ekstragranularnim komponentama:
(f) 1-25 masenih postotaka jednog ili više punila;
(g) 0-8 masenih postotaka jednog ili više sredstava za raspadanje;
(h) 0.1-3 masenih postotaka jednog ili više sredstava za podmazivanje.
2. Farmaceutski prihvatljiv pripravak koji sadrži 10-70 masenih postotaka neratinib maleata i 5-15 masenih postotaka povidona.
3. Farmaceutski prihvatljiv pripravak koji sadrži intragranularne komponente: 10-70 masenih postotaka neratinib maleata i 5-15 masenih postotaka povidona; i ekstragranularne komponente: mikrokristalnu celulozu, krospovidon i magnezijev stearat.
4. Farmaceutski prihvatljiv pripravak koji sadrži intragranularne komponente:
(a) 10-70 masenih postotaka neratinib maleata;
(b) 15-65 masenih postotaka manitola, mikrokristalne celuloze ili njihove kombinacije;
(c) 0.5-8 masenih postotaka krospovidona, kroskarmeloze natrija ili njihove kombinacije;
(d) 0.2-8 masenih postotaka koloidnog silicijevog dioksida; i
(e) 5-15 masenih postotaka povidona;
i ekstragranularne komponente:
(f) 1-25 masenih postotaka mikrokristalne celuloze;
(g) 1-8 masenih postotaka krospovidona; i
(h) 0.5-3 masenih postotaka magnezijevog stearata.
5. Tableta ili suho punjena kapsula koja sadrži pripravak u skladu s patentnim zahtjevom 4.
6. Pripravak u skladu s patentnim zahtjevom 4, pri čemu je količina neratinib maleata oko 41 masenih postotaka; ili pri čemu je količina neratinib maleata oko 35 masenih postotaka.
7. Pripravak u skladu s patentnim zahtjevom 4, pri čemu je količina manitola i mikrokristalne celuloze, kao intragranularne komponente, oko 50 masenih postotaka.
8. Pripravak u skladu s patentnim zahtjevom 4, pri čemu je količina krospovidona, kao intragranularne komponente, oko 3 masenih postotaka; i/ili pri čemu je količina povidona, kao intragranularne komponente, oko 5 masenih postotaka.
9. Pripravak u skladu s bilo kojim od patentnih zahtjeva 4 i 6-8, u obliku oralne doze od 40 mg, 80 mg ili 240 mg.
10. Pripravak u skladu s patentnim zahtjevom 4, pri čemu pripravak sadrži
(b) manitol i mikrokristalnu celulozu i
(c) krospovidon.
11. Pripravak u skladu s patentnim zahtjevom 4, pri čemu pripravak sadrži intragranularnu komponentu:
(a) 35.00 masenih postotaka neratinib maleata kao neratinib slobodna baza;
(b) 38.94 masenih postotaka manitola;
(c) 10.56 masenih postotaka mikrokristalne celuloze;
(d) 3.00 masenih postotaka krospovidona;
(e) 2.00 masenih postotaka koloidnog silicijevog dioksida; i
(f) 5.00 masenih postotaka povidona;
i kao ekstragranularne komponente:
(g) 1.50 masenih postotaka mikrokristalne celuloze;
(h) 2.00 masenih postotaka krospovidona; i
(i) 2.00 masenih postotaka magnezijevog stearata; i pri čemu pripravak nadalje sadrži filmski premaz.
12. Način za pripremu farmaceutski prihvatljivog pripravka sadrži: prskanje 5-15 masenih postotaka jednog ili više sredstava za modificiranje površine na intragranularne komponente granulacije, navedene intragranularne komponente sadrže:
(a) 10-70 masenih postotaka neratinib maleata;
(b) 15-65 masenih postotaka jednog ili više punila;
(c) 0-8 masenih postotaka jednog ili više sredstava za raspadanje;
(d) 0.2-8 masenih postotaka jednog ili više sredstava za klizanje; i
(e) 5-15 masenih postotaka jednog ili više sredstava za modificiranje površine;
pri čemu su navedene obložene intragranularne komponente kombinirane s ekstragranularnim komponentama granulacije, navedene ekstragranularne komponente sadrže:
(f) 1-25 masenih postotaka jednog ili više punila;
(g) 0-8 masenih postotaka jednog ili više sredstava za raspadanje; i
(h) 0.1-3 masenih postotaka jednog ili više sredstava za podmazivanje.
13. Način u skladu s patentnim zahtjevom 12, pri čemu je sredstvo za modificiranje površine povidon.
14. Farmaceutski prihvatljiv pripravak u skladu s bilo kojim od patentnih zahtjeva 1 do 4 i 6 do 11 ili tableta ili suho punjena kapsula u skladu s patentnim zahtjevom 5 za uporabu u načinu liječenja karcinoma.
15. Pripravak u skladu s patentnim zahtjevom 11, pri čemu je količina filmskog premaza oko 3 masena postotka.
16. Farmaceutski pripravak u skladu s patentnim zahtjevom 15, pri čemu je filmski premaz crven, žut ili ružičast.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25940309P | 2009-11-09 | 2009-11-09 | |
| EP10779339.0A EP2498756B2 (en) | 2009-11-09 | 2010-11-02 | Tablet formulations of neratinib maleate |
| PCT/IB2010/054964 WO2011055303A1 (en) | 2009-11-09 | 2010-11-02 | Tablet formulations of neratinib maleate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HRP20192026T1 true HRP20192026T1 (hr) | 2020-02-07 |
| HRP20192026T4 HRP20192026T4 (hr) | 2023-03-31 |
Family
ID=43478191
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20192026TT HRP20192026T4 (hr) | 2009-11-09 | 2010-11-02 | Formulacija tableta od neratinib maleata |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US8518446B2 (hr) |
| EP (3) | EP3566697A1 (hr) |
| JP (3) | JP5835883B2 (hr) |
| CN (2) | CN103893140B (hr) |
| AR (2) | AR078952A1 (hr) |
| AU (1) | AU2010316683B2 (hr) |
| CA (1) | CA2780428C (hr) |
| CY (1) | CY1122330T1 (hr) |
| DK (1) | DK2498756T4 (hr) |
| ES (1) | ES2757882T5 (hr) |
| FI (1) | FI2498756T4 (hr) |
| HR (1) | HRP20192026T4 (hr) |
| HU (1) | HUE046606T2 (hr) |
| LT (1) | LT2498756T (hr) |
| NZ (1) | NZ599763A (hr) |
| PL (1) | PL2498756T5 (hr) |
| PT (1) | PT2498756T (hr) |
| RS (1) | RS59599B2 (hr) |
| SI (1) | SI2498756T2 (hr) |
| TW (1) | TWI466690B (hr) |
| WO (1) | WO2011055303A1 (hr) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10351448A1 (de) * | 2003-11-04 | 2005-06-09 | Bayer Healthcare Ag | Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften |
| PL1848414T3 (pl) | 2005-02-03 | 2011-10-31 | Wyeth Llc | Sposób leczenia nowotworu opornego na gefitinib |
| PE20070763A1 (es) | 2005-11-04 | 2007-08-08 | Wyeth Corp | COMBINACIONES ANTINEOPLASICAS DE UN INHIBIDOR DE mTOR, TRASTUZUMAB Y/O HKI-272 |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| US9439897B2 (en) | 2007-11-06 | 2016-09-13 | Immunolight, Llc | Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders |
| CN102641270A (zh) | 2008-06-17 | 2012-08-22 | 惠氏有限责任公司 | 含有hki-272和长春瑞滨的抗肿瘤组合 |
| CN102202667A (zh) | 2008-08-04 | 2011-09-28 | 惠氏有限责任公司 | 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合 |
| MX356593B (es) | 2009-04-06 | 2018-06-05 | Wyeth Llc | Régimen de tratamiento que utiliza neratinib para cáncer de mama. |
| WO2011056741A2 (en) * | 2009-11-09 | 2011-05-12 | Wyeth Llc | Coated drug spheroids and uses thereof for eliminating or reducing conditions such as emesis and diarrhea |
| RS59599B2 (sr) * | 2009-11-09 | 2023-03-31 | Wyeth Llc | Formulacije tableta neratinib maleata |
| PT3738434T (pt) | 2011-12-28 | 2023-11-13 | Global Blood Therapeutics Inc | Intermediários para obter compostos de benzaldeído substituído e métodos para a sua utilização no aumento da oxigenação de tecidos |
| ES2790358T3 (es) | 2011-12-28 | 2020-10-27 | Global Blood Therapeutics Inc | Compuestos de heteroaril aldehído sustituido y métodos para su uso en el aumento de la oxigenación tisular |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CN111454200A (zh) | 2013-03-15 | 2020-07-28 | 全球血液疗法股份有限公司 | 化合物及其用于调节血红蛋白的用途 |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| CA2902711C (en) | 2013-03-15 | 2021-07-06 | Global Blood Therapeutics, Inc. | Substituted pyridinyl-6-methoxy-2-hydroxybenzaldehyde derivatives and pharmaceutical compositions thereof useful for the modulation of hemoglobin |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| SG10201802911RA (en) | 2013-03-15 | 2018-05-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| US9818967B2 (en) * | 2013-06-28 | 2017-11-14 | Universal Display Corporation | Barrier covered microlens films |
| CN104337782A (zh) * | 2013-08-02 | 2015-02-11 | 山东新时代药业有限公司 | 一种甲磺酸伊马替尼片剂 |
| EA201992707A1 (ru) | 2013-11-18 | 2020-06-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SI3102208T1 (sl) | 2014-02-07 | 2021-07-30 | Global Blood Therapeutics, Inc. | Kristalinični polimorf proste baze 2-hidroksi-6-((2-(1-izopropil-1H-pirazol-5-IL)piridin-3-IL)metoksi)- benzaldehida |
| CA2939345C (en) | 2014-02-17 | 2022-05-31 | Children's National Medical Center | Method and system for providing recommendation for optimal execution of surgical procedures |
| DK3172209T3 (da) * | 2014-07-25 | 2021-02-22 | Novartis Ag | Tabletformulering med 2-fluor-n-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamid |
| US10016471B2 (en) | 2015-06-29 | 2018-07-10 | Phloronol, Inc. | Solid pharmaceutical compositions of brown algae |
| MA43373A (fr) | 2015-12-04 | 2018-10-10 | Global Blood Therapeutics Inc | Régimes posologiques pour 2-hydroxy-6-((2- (1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)méthoxy)benzaldéhyde |
| CN106831710A (zh) * | 2015-12-07 | 2017-06-13 | 常州爱诺新睿医药技术有限公司 | 一种无定型来那替尼或其药学上可接受的盐与药用辅料的固体分散体及其制备方法 |
| CN106913529B (zh) * | 2015-12-24 | 2020-12-04 | 江苏恒瑞医药股份有限公司 | 一种来那替尼或其可药用盐药物组合物的制备方法 |
| CA2937365C (en) * | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
| TWI752307B (zh) | 2016-05-12 | 2022-01-11 | 美商全球血液治療公司 | 新穎化合物及製造化合物之方法 |
| CA3036053A1 (en) * | 2016-09-07 | 2018-03-15 | Celgene Corporation | Tablet compositions |
| TWI778983B (zh) * | 2016-10-12 | 2022-10-01 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| KR20190140011A (ko) * | 2017-04-28 | 2019-12-18 | 아사나 바이오사이언시스 엘엘씨 | 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형 |
| CA3079916A1 (en) * | 2017-10-24 | 2019-05-02 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition containing quinoline derivative |
| US11014884B2 (en) | 2018-10-01 | 2021-05-25 | Global Blood Therapeutics, Inc. | Modulators of hemoglobin |
| IL295007A (en) | 2020-01-31 | 2022-09-01 | Nanocopoeia Llc | Amorphous nilotinib microparticles and uses thereof |
| WO2021222739A1 (en) * | 2020-04-30 | 2021-11-04 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib |
| US20220378788A1 (en) * | 2020-04-30 | 2022-12-01 | Nanocopoeia, Llc | Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib and in vitro characterization thereof |
| TW202345857A (zh) * | 2022-03-08 | 2023-12-01 | 美商昂科斯克塞爾醫療有限責任公司 | 他波司他之穩定調配物 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW442301B (en) * | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
| US6288082B1 (en) | 1998-09-29 | 2001-09-11 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6297258B1 (en) | 1998-09-29 | 2001-10-02 | American Cyanamid Company | Substituted 3-cyanoquinolines |
| US6384051B1 (en) | 2000-03-13 | 2002-05-07 | American Cyanamid Company | Method of treating or inhibiting colonic polyps |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| US20050142192A1 (en) | 2003-10-15 | 2005-06-30 | Wyeth | Oral administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives |
| AR046544A1 (es) * | 2003-10-15 | 2005-12-14 | Wyeth Corp | Administracion oral de acido [2- (8,9 - dioxo - 2,6 - diazabiciclo [5.2.0] non -1 (7) - en - 2 - il ) alquil] fosfonico yderivados |
| AR051388A1 (es) * | 2004-10-13 | 2007-01-10 | Wyeth Corp | Analogos de 17-hidroxiwortmanina como inhibidores de pi3k |
| WO2006085168A2 (en) | 2005-01-07 | 2006-08-17 | Ranbaxy Laboratories Limited | Solid oral dosage forms of ziprasidone containing colloidal silicone dioxide |
| AU2006241113B2 (en) * | 2005-04-28 | 2011-08-18 | Wyeth | Micronized tanaproget, compositions, and methods of preparing the same |
| EP1948180B1 (en) * | 2005-11-11 | 2013-03-13 | Boehringer Ingelheim International GmbH | Combination treatment of cancer comprising egfr/her2 inhibitors |
| JP2007169273A (ja) * | 2005-11-28 | 2007-07-05 | Takeda Chem Ind Ltd | 杵付着を改善した医薬製剤 |
| JP2007211005A (ja) * | 2006-01-16 | 2007-08-23 | Ono Pharmaceut Co Ltd | 固形製剤用組成物および固形製剤 |
| TW200806282A (en) * | 2006-05-05 | 2008-02-01 | Wyeth Corp | Solid dosage formulations |
| MX2009007254A (es) * | 2007-01-12 | 2009-08-12 | Wyeth Corp | Composiciones de tableta en tableta. |
| WO2008093878A1 (en) * | 2007-02-01 | 2008-08-07 | Takeda Pharmaceutical Company Limited | Tablet preparation without causing a tableting trouble |
| JP2009089982A (ja) * | 2007-10-11 | 2009-04-30 | Ohara Yakuhin Kogyo Kk | 打錠用造粒物の造粒方法 |
| WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| EP2448563A2 (en) * | 2009-07-02 | 2012-05-09 | Wyeth LLC | 3-cyanoquinoline tablet formulations and uses thereof |
| RS59599B2 (sr) * | 2009-11-09 | 2023-03-31 | Wyeth Llc | Formulacije tableta neratinib maleata |
-
2010
- 2010-11-02 RS RS20191417A patent/RS59599B2/sr unknown
- 2010-11-02 EP EP19154710.8A patent/EP3566697A1/en active Pending
- 2010-11-02 HU HUE10779339A patent/HUE046606T2/hu unknown
- 2010-11-02 SI SI201031952T patent/SI2498756T2/sl unknown
- 2010-11-02 PL PL10779339.0T patent/PL2498756T5/pl unknown
- 2010-11-02 FI FIEP10779339.0T patent/FI2498756T4/fi active
- 2010-11-02 CN CN201410082103.7A patent/CN103893140B/zh active Active
- 2010-11-02 EP EP22169771.7A patent/EP4066821A1/en active Pending
- 2010-11-02 HR HRP20192026TT patent/HRP20192026T4/hr unknown
- 2010-11-02 WO PCT/IB2010/054964 patent/WO2011055303A1/en active Application Filing
- 2010-11-02 ES ES10779339T patent/ES2757882T5/es active Active
- 2010-11-02 AU AU2010316683A patent/AU2010316683B2/en active Active
- 2010-11-02 CA CA2780428A patent/CA2780428C/en active Active
- 2010-11-02 NZ NZ599763A patent/NZ599763A/en unknown
- 2010-11-02 EP EP10779339.0A patent/EP2498756B2/en active Active
- 2010-11-02 LT LT10779339T patent/LT2498756T/lt unknown
- 2010-11-02 PT PT107793390T patent/PT2498756T/pt unknown
- 2010-11-02 DK DK10779339.0T patent/DK2498756T4/da active
- 2010-11-02 CN CN201080060546.6A patent/CN102724970B/zh active Active
- 2010-11-05 US US12/940,808 patent/US8518446B2/en active Active
- 2010-11-08 TW TW99138396A patent/TWI466690B/zh active
- 2010-11-08 JP JP2010249385A patent/JP5835883B2/ja active Active
- 2010-11-09 AR ARP100104156A patent/AR078952A1/es not_active Application Discontinuation
-
2013
- 2013-08-21 US US13/972,764 patent/US8790708B2/en active Active
-
2015
- 2015-02-06 JP JP2015021870A patent/JP2015091882A/ja not_active Withdrawn
-
2017
- 2017-02-06 JP JP2017019429A patent/JP2017075192A/ja not_active Withdrawn
-
2018
- 2018-11-14 AR ARP180103329A patent/AR114143A2/es not_active Application Discontinuation
-
2019
- 2019-11-14 CY CY20191101200T patent/CY1122330T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20192026T1 (hr) | Formulacija tableta od neratinib maleata | |
| JP2011098964A5 (hr) | ||
| HRP20200138T1 (hr) | Kombinirana formulacija dva antivirusna spoja | |
| HRP20191094T1 (hr) | Formulacije 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona | |
| HRP20201055T1 (hr) | Farmaceutske formulacije nitazoksanida s kontroliranim oslobađanjem | |
| RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
| RU2015143515A (ru) | Твердые таблетки и капсулы модифицированного высвобождения бензонатата | |
| HRP20220902T3 (hr) | Pripravci i njihova upotreba u liječenju multiple skleroze | |
| BR112019001572A2 (pt) | nova formulação administrável por via oral | |
| MX2007006212A (es) | Medicamento oral para liberacion modificada de al menos un principio activo bajo forma multimicrocapsular. | |
| BRPI0414311A (pt) | formas de dosagem de liberação controlada | |
| JP2016516698A5 (hr) | ||
| HRP20161340T1 (hr) | Formulacije darunavira | |
| RS54329B1 (en) | PHARMACEUTICAL COMPOSITIONS CONTAINING RIFAXIMINE, PROCEDURES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF VAGINAL INFECTIONS | |
| ATE350040T1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| JP2008543936A5 (hr) | ||
| HRP20211862T1 (hr) | Pripravci za i postupci liječenja anemije | |
| CA2440588A1 (en) | Chronotherapeutic dosage forms | |
| RU2016122609A (ru) | Составы соединений азаиндола | |
| AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
| JP2007091633A (ja) | メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物 | |
| JP2010527347A5 (hr) | ||
| RU2006122517A (ru) | Фармацевтический состав для прямого прессования, предназначенный для перорального введения cci-779 | |
| GT200900089A (es) | Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine | |
| HRP20100120T1 (hr) | Formulacije s valsartanom |